Hypofractionated re-irradiation for diffuse intrinsic pontine glioma.

Abstract

Re-irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We report our institutional experience of reRT for DIPG, which includes hypofractionation (HF). We reviewed pediatric patients treated with brainstem reRT for DIPG at our institution from 2012 to 2022. Patients were grouped by HF or CF. Outcomes included steroid use, and overall survival (OS) was measured from both diagnosis and start of reRT. Of 22 patients who received reRT for DIPG, two did not complete their course due to clinical decline. Of the 20 who completed reRT, the dose was 20-30Gy in 2-Gy fractions (n=6) and 30-36Gy in 3-Gy fractions (n=14). Median age was 5years (range: 3-14), median interval since initial RT was 8months (range: 3-20), and 12 received concurrent bevacizumab. Median OS from diagnosis was 18months [95% confidence interval: 17-24]. Median OS from start of reRT for HF versus CF was 8.2 and 7.5months, respectively (p=.20). Thirteen (93%) in the HF group and three (75%) in the CF group tapered pre-treatment steroid dose down or off within 2months after reRT due to clinical improvement. There was no significant difference in steroid taper between HF and CF (p=.4). No patients developed radionecrosis. reRT with HF achieved survival duration comparable to published outcomes and effectively palliated symptoms. Future investigation of this regimen in the context of new systemic therapies and upfront HF is warranted.